Zhao, Jean J.

CDK4/6 inhibition triggers anti-tumour immunity

Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature

Cancer Immunotherapy and BiomarkersAdvanced Breast Cancer Therapies

Cited by 1,513

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 1,460

PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer

Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports

PARP inhibition in cancer therapyCancer Immunotherapy and Biomarkers

Cited by 572

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

Goel, S., Wang, Q., Watt, A. C., Tolaney, S. M., Dillon, D. A., Li, W., Ramm, S., Palmer, A. C., Yuzugullu, H., Varadan, V., et al. (2016) · Cancer Cell

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 470

Bioprinting for cancer research

Knowlton, S., Onal, S., Yu, C. H., Zhao, J. J., & Tasoglu, S. (2015) · Trends in Biotechnology

3D Printing in Biomedical ResearchCellular Mechanics and Interactions

Cited by 361

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

Hanker, A. B., Pfefferle, A. D., Balko, J. M., Kuba, M. G., Young, C. D., Sánchez, V., Sutton, C. R., Cheng, H., Perou, C. M., Zhao, J. J., et al. (2013) · Proceedings of the National Academy of Sciences

HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 203

Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas

Pal, S., Kozono, D., Yang, X., Fendler, W., Fitts, W., Ni, J., Alberta, J. A., Zhao, J., Liu, K. X., Bian, J., et al. (2018) · Cancer Research

Glioma Diagnosis and TreatmentChromatin Remodeling and Cancer

Cited by 101

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer

Wang, D., Wang, M., Jiang, N., Zhang, Y., Bian, X., Wang, X., Roberts, T. M., Zhao, J. J., Liu, P., & Cheng, H. (2016) · Oncotarget

PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment

Cited by 88

Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides

Wang, D., Wang, Q., Wang, Y., Chen, P., Lu, X., Jia, F., Sun, Y., Sun, T., Zhang, L., Che, F., et al. (2022) · Proceedings of the National Academy of Sciences

RNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

Cited by 43

PI3K alpha and delta promote hematopoietic stem cell activation

Hemmati, S., Sinclair, T., Tong, M., Bartholdy, B., Okabe, R. O., Ames, K., Ostrodka, L., Haque, T., Kaur, I., Mills, T. S., et al. (2019) · JCI Insight

Hematopoietic Stem Cell TransplantationPI3K/AKT/mTOR signaling in cancer

Cited by 40